Tsirpanlis George, Chatzipanagiotou Stylianos, Ioannidis Anastasios, Moutafis Spyros, Poulopoulou Cornelia, Nicolaou Chrysoula
Renal Unit, Alexandra General Hospital, Kriezi 61, Polydroso, Marousi, 15125 Athens, Greece.
Nephrol Dial Transplant. 2003 May;18(5):918-23. doi: 10.1093/ndt/gfg085.
Chlamydia pneumoniae has been implicated as an inflammatory agent in atherosclerosis. Clinical studies in this field have yielded conflicting results, which may have resulted from a lack of standardization for C.pneumoniae detection. We attempted to accurately estimate C.pneumoniae prevalence and to examine whether C.pneumoniae is associated with atherosclerosis and inflammation in haemodialysis (HD) patients. To do this, we assessed C.pneumoniae presence by a combination of methods and correlated its levels with inflammatory and atherosclerotic indexes in these patients.
Chlamydia pneumoniae was identified by polymerase chain reaction (PCR) in DNA extracted from cell cultures inoculated with patient buffy coats and by serum IgG antibodies against C.pneumoniae (IgGCp). Inflammation was assessed by C-reactive protein and serum amyloid A and atherosclerosis was evaluated from clinical and laboratory data.
Of the 130 patients, only nine had viable C.pneumoniae in peripheral blood mononuclear cells (PBMCs) while 64 had serum IgGCp. Although patients with viable C.pneumoniae had higher atherosclerotic scores, seropositive and negative patients showed similar scores. Patients with atherosclerosis exhibited higher inflammatory indexes. Neither patients with detectable C.pneumoniae in PBMCs nor seropositive subjects had higher inflammation than negative patients.
We found that viable C.pneumoniae in PBMCs, assessed by cell culture and PCR, was present in a small percentage of HD patients and was correlated with atherosclerosis. Seropositivity was much higher in HD patients but was not associated with viable C.pneumoniae or with atherosclerosis. Further studies in HD patients using high sensitivity and specificity methods in larger populations will be necessary to clarify the relationship between C.pneumoniae and atherosclerosis.
肺炎衣原体被认为是动脉粥样硬化中的一种炎症因子。该领域的临床研究结果相互矛盾,这可能是由于肺炎衣原体检测缺乏标准化所致。我们试图准确估计肺炎衣原体的患病率,并研究肺炎衣原体是否与血液透析(HD)患者的动脉粥样硬化和炎症相关。为此,我们通过多种方法联合评估肺炎衣原体的存在情况,并将其水平与这些患者的炎症和动脉粥样硬化指标相关联。
通过聚合酶链反应(PCR)在接种患者血沉棕黄层的细胞培养物提取的DNA中鉴定肺炎衣原体,并通过抗肺炎衣原体血清IgG抗体(IgGCp)进行检测。通过C反应蛋白和血清淀粉样蛋白A评估炎症,并根据临床和实验室数据评估动脉粥样硬化。
在130例患者中,仅9例在外周血单核细胞(PBMC)中有活的肺炎衣原体,而64例有血清IgGCp。虽然有活的肺炎衣原体的患者动脉粥样硬化评分较高,但血清学阳性和阴性患者的评分相似。有动脉粥样硬化的患者炎症指标较高。PBMC中可检测到肺炎衣原体的患者和血清学阳性患者的炎症均不高于阴性患者。
我们发现,通过细胞培养和PCR评估,PBMC中有活的肺炎衣原体的HD患者比例较小,且与动脉粥样硬化相关。HD患者血清学阳性率高得多,但与活的肺炎衣原体或动脉粥样硬化无关。有必要在更多人群中对HD患者采用高灵敏度和特异性方法进行进一步研究,以阐明肺炎衣原体与动脉粥样硬化之间的关系。